BidaskClub downgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a buy rating to a hold rating in a research report released on Tuesday.

A number of other research analysts also recently issued reports on the company. Leerink Swann boosted their price objective on Amicus Therapeutics from $20.00 to $24.00 and gave the company an outperform rating in a research note on Thursday, February 8th. Robert W. Baird set a $20.00 price objective on Amicus Therapeutics and gave the company a buy rating in a research note on Wednesday, February 7th. ValuEngine upgraded Amicus Therapeutics from a sell rating to a hold rating in a research note on Friday, February 2nd. Zacks Investment Research upgraded Amicus Therapeutics from a strong sell rating to a hold rating in a research note on Wednesday, January 17th. Finally, Cowen reiterated a buy rating and set a $22.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $19.06.

Amicus Therapeutics (FOLD) opened at $14.62 on Tuesday. The stock has a market capitalization of $2,430.00, a P/E ratio of -7.99 and a beta of 1.45. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. Amicus Therapeutics has a 52 week low of $5.87 and a 52 week high of $17.40.

In other Amicus Therapeutics news, insider Jay Barth sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $16.80, for a total value of $336,000.00. Following the completion of the transaction, the insider now directly owns 105,409 shares in the company, valued at approximately $1,770,871.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John F. Crowley sold 12,206 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $13.52, for a total value of $165,025.12. Following the completion of the transaction, the chief executive officer now owns 340,207 shares of the company’s stock, valued at $4,599,598.64. The disclosure for this sale can be found here. Insiders sold a total of 250,390 shares of company stock valued at $3,620,581 over the last 90 days. 3.40% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Alliancebernstein L.P. boosted its stake in Amicus Therapeutics by 16.3% in the 2nd quarter. Alliancebernstein L.P. now owns 205,836 shares of the biopharmaceutical company’s stock worth $2,073,000 after purchasing an additional 28,800 shares during the period. Bank of Nova Scotia bought a new position in shares of Amicus Therapeutics during the 2nd quarter valued at approximately $1,944,000. American International Group Inc. boosted its position in shares of Amicus Therapeutics by 23.1% during the 3rd quarter. American International Group Inc. now owns 109,628 shares of the biopharmaceutical company’s stock valued at $1,653,000 after acquiring an additional 20,597 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Amicus Therapeutics by 5.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after acquiring an additional 430,486 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Amicus Therapeutics by 2.2% during the 2nd quarter. State Street Corp now owns 5,892,564 shares of the biopharmaceutical company’s stock valued at $59,332,000 after acquiring an additional 125,635 shares during the last quarter.

WARNING: “Amicus Therapeutics (FOLD) Downgraded by BidaskClub to “Hold”” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2018/02/14/amicus-therapeutics-fold-downgraded-by-bidaskclub-to-hold.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.